Checking around in many pharma / Bio company sites or LinkedIn, etc., most folks seem to be in it for the buy out possibility. Here we have a belief that PR and most of us here on HC are looking longer term for increased earnings and dividends thru partnerships with big Pharma doing the distributions.
Interview 3 with an FDA Process Expert, page-15
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 23.0¢ | $74.06K | 320.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 102830 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 703 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |